GSK On Track For Six Regulatory Submissions In The Second Half
R&D President Hal Barron outlined progress reenergizing GSK's pharma pipeline and highlighted the key milestones ahead in 2019 during the company's second quarter call.
R&D President Hal Barron outlined progress reenergizing GSK's pharma pipeline and highlighted the key milestones ahead in 2019 during the company's second quarter call.